Eli Lilly and Company $LLY Stake Lifted by Riverpark Capital Management LLC

Riverpark Capital Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 8.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,363 shares of the company’s stock after buying an additional 276 shares during the period. Eli Lilly and Company makes up about 4.3% of Riverpark Capital Management LLC’s holdings, making the stock its 6th biggest holding. Riverpark Capital Management LLC’s holdings in Eli Lilly and Company were worth $2,622,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Lazard Freres Gestion S.A.S. increased its position in shares of Eli Lilly and Company by 114.3% during the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after acquiring an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC increased its holdings in Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after purchasing an additional 39 shares during the last quarter. Capital Advisors Inc. OK boosted its stake in shares of Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after buying an additional 429 shares during the last quarter. Family CFO Inc acquired a new stake in shares of Eli Lilly and Company during the second quarter worth approximately $54,000. Finally, Duquesne Family Office LLC increased its stake in shares of Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after buying an additional 32,640 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,109.09 on Wednesday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm’s 50 day moving average is $869.19 and its two-hundred day moving average is $792.66. The firm has a market capitalization of $1.05 trillion, a P/E ratio of 72.49, a PEG ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.11.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Guggenheim reaffirmed a “buy” rating and set a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 16th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Daiwa Capital Markets increased their target price on shares of Eli Lilly and Company from $700.00 to $940.00 in a report on Monday, November 10th. Finally, Cantor Fitzgerald lifted their price target on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,047.50.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.